Healthcare / Diagnostics & ResearchBSE
$130.65
+3.88 (+3.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $7.9M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
2613.0x
↑EV/EBITDA
69.0x
↑ROE
0.4%
↑Gross Margin
76.6%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+20.0%
FCF CAGR
—
FCF margin
3.0%
FCF / Net income
14.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $249.8M · net income $513000.0 · FCF $7.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $249.8M | $249.8M | $220.0M | $132.0M | $144.6M |
| Net Income | $513000.00 | $513000.00 | $20.7M | $-26.7M | $-887000.00 |
| EBITDA | $19.8M | $19.8M | $39.1M | $-8.2M | $18.6M |
| EPS | — | — | 2.01 | -2.60 | -0.09 |
| Gross Margin | 76.6% | 76.6% | 78.7% | 74.3% | 78.8% |
| Operating Margin | -0.3% | -0.3% | 9.2% | -20.5% | 0.1% |
| Net Margin | 0.2% | 0.2% | 9.4% | -20.2% | -0.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.16 | 0.17 | 0.18 |
| Current Ratio | 1.44 | 1.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.5M | $7.5M | $15.3M | $7.9M | $-1.5M |
| Returns | |||||
| ROE | 0.4% | 0.4% | 17.0% | -26.3% | -0.7% |
| Valuation | |||||
| P/E | 2613.00 | 2613.00 | 34.55 | — | — |
| EV/EBITDA | 68.99 | 68.99 | 18.36 | — | — |
| P/B | 10.99 | 10.99 | 5.89 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 13.6% | 13.6% | 66.6% | -8.7% | — |
| EPS Growth | — | — | 177.3% | -2788.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+127.8%
Start / end P/E
n/dx → n/dx
EPS bridge
2.01 → n/d
Residual
+127.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.